Vertebrate immune systems have evolved sophisticated genetic mechanisms to generate T-cell receptor and antibody repertoires, which are combinatorial libraries of affinity molecules capable of distinguishing between self and non-self. Recent data highlight the delicate balance in higher mammals between energy utilization, robust immune defense against pathogens and autoimmunity 1 . In humans, loss of tolerance to self-antigens results in a number of diseases including type I diabetes, multiple sclerosis, lupus and rheumatoid arthritis. Knowledge of the self-antigens involved in autoimmune processes is important not only for understanding disease etiology but also for developing accurate diagnostic tests. In addition, physicians may someday use antigenspecific therapies to destroy or disable autoreactive immune cells.
A r t i c l e s
Vertebrate immune systems have evolved sophisticated genetic mechanisms to generate T-cell receptor and antibody repertoires, which are combinatorial libraries of affinity molecules capable of distinguishing between self and non-self. Recent data highlight the delicate balance in higher mammals between energy utilization, robust immune defense against pathogens and autoimmunity 1 . In humans, loss of tolerance to self-antigens results in a number of diseases including type I diabetes, multiple sclerosis, lupus and rheumatoid arthritis. Knowledge of the self-antigens involved in autoimmune processes is important not only for understanding disease etiology but also for developing accurate diagnostic tests. In addition, physicians may someday use antigenspecific therapies to destroy or disable autoreactive immune cells.
Traditional approaches for identifying autoantibody targets have relied largely on the expression of fragmented cDNA libraries as polypeptides fused to the capsid proteins of bacteriophage. Notable technical limitations of this method include the small fraction of clones expressing coding sequences in the correct reading frame (with a lower bound of 6%) 2 , and the highly skewed representation of differentially expressed cDNAs. Nevertheless, this approach has led to the discovery of many important autoantigens [3] [4] [5] . Strides have been made to improve peptide display systems 6, 7 , but there remains an unmet need for better display libraries and methods to analyze binding interactions.
We have therefore constructed a synthetic representation of the complete human proteome, which we engineered for display as peptides on the surface of T7 phage. This library (T7-Pep) was extensively characterized and found to be both faithful to its in silico design and uniform in its representation. Autoantibodies within a complex mixture can thus be used to enrich for phage-displaying autoantigenic peptides. The population of enriched phage can then be analyzed by high-throughput DNA sequencing. This approach provides several advantages over traditional methods, including comprehensive and unbiased proteomic analysis, and peptide enrichment quantification using a streamlined, multiplexed protocol requiring just one round of enrichment. We have applied phage immunoprecipitation sequencing (PhIP-Seq) to interrogate the autoantibody repertoire in the spinal fluid of patients with neurological autoimmunity and identified both known and novel autoantigens. Furthermore, to demonstrate how this approach can be used more generally to identify peptide-protein interactions, we used it to recover proteins known to interact with replication protein A2 (RPA2).
RESULTS

Construction and characterization of the T7-Pep library
To create a synthetic representation of the human proteome, we began by extracting all open reading frame (ORF) sequences available from build 35.1 of the human genome (24, 239 ORFs; 23% of which had 'predicted' status). When there were multiple isoforms of the same protein, we randomly selected one representative ORF. We modified the codon usage by eliminating restriction sites used for cloning and by substituting very low abundance codons in Escherichia coli, the T7 host, with more abundant synonymous codons. We then divided each ORF into overlapping sequences of 108 nucleotides encoding 36-amino acid peptides (Fig. 1a) . Consecutive peptides overlapped by seven residues, the estimated size of a linear epitope. Finally, the stop codon of each ORF was removed so that all peptides could be cloned in-frame with a C-terminal FLAG tag.
The final library design includes 413,611 peptides spanning the entire coding region of the human genome. The peptide-coding sequences were synthesized as 140-mer oligonucleotides with primer sequences on releasable DNA microarrays in 19 pools of 22,000 oligos each, PCR-amplified and cloned into a derivative of the T7Select 10-3b phage display vector (Fig. 1b, i and Online Methods). We also generated two additional libraries comprising the N-terminal and C-terminal peptidomes (T7-NPep, T7-CPep), which encode only the first and last 24 codons from each ORF, for use in future studies.
The extent of vector re-ligation, multiple insertions, mutations and correct in-frame phage-displayed peptides was determined by plaque PCR analysis (Supplementary Table 1) , clone sequencing (Fig. 1c) and FLAG expression (Supplementary Table 2 ) of randomly sampled phage from all subpools. Sequencing revealed that 83% of the inserts lacked frameshifting mutations. These data indicate that a much greater fraction of in-frame, ORF-derived peptides is expressed by our synthetic libraries compared to those constructed from cDNA ( Table 1) .
After combining 5 × 10 8 phage from each subpool and then amplifying and Illumina sequencing the final library at a median depth of 45-fold coverage (Fig. 1d) , we detected 91.2% of the expected clones. Chao1 analysis 8 was done to estimate the actual library complexity (assuming infinite sampling), which predicted that >91.8% of the library was represented (Supplementary Fig. 1 ). In addition, the T7-Pep library is highly uniform, with 78% of the library members within tenfold abundance (having been sequenced between 10 and 100 times). These data suggest that our library encodes a much more complete and uniform representation of the human proteome than can otherwise be achieved with existing technologies ( Table 1) . 
A r t i c l e s
We next optimized a phage immunoprecipitation protocol for detecting antibody-peptide interactions within complex mixtures by systematically varying parameters such as the relative concentrations of antibody and phage, number of washes and type of beads. (Supplementary Fig. 2 ). Our streamlined procedure consists of incubating T7-Pep with unmodified patient cerebrospinal spinal fluid, immunoprecipitating phage-antibody complexes on beads with Protein A and Protein G, washing away unbound phage and then subjecting the enriched phage population to PCR amplification and deep-sequencing DNA analysis (Fig. 1b) .
Analysis of a PND patient with NOVA autoantibodies Tumor antigens often elicit cellular and humoral immune responses, which may limit disease progression 9 . In rare cases, such immune responses recognize central nervous system (CNS) antigens, triggering a devastating autoimmune process called paraneoplastic neurological disorder (PND). Clinical symptoms of PND are heterogeneous and often correlate with the CNS autoantigens involved. PND has served as a model for CNS autoimmunity, and the application of phage display to PND autoantigen discovery has met with much success 3, 10 .
To assess the performance of PhIP-Seq for autoantigen discovery, we examined a sample of cerebrospinal fluid from a 63-year-old female (patient A) with non-small cell lung cancer (NSCLC) who had a PND syndrome and was previously found to have NOVA (neurooncological ventral antigen) autoantibodies 11 . The NOVA autoantigen is commonly targeted in PND triggered by lung or gynecological cancers, and results in ataxia with or without opsoclonus or myoclonus. A final concentration of 2 µg/ml of patient cerebrospinal fluid antibody was spiked with 2 ng/ml of a commercial antibody specific to SAPK4, which was used as a positive control to monitor enrichment of the SAPK4 peptide library member. Despite extensive washing, 298,667 unique clones (83% of the input library) were found in the immunoprecipitate. A significant correlation was observed between the abundance of input clones and immunoprecipitated clones (Fig. 2a) , likely owing to weak nonspecific interactions with the beads.
We used a two-parameter, generalized Poisson model to approximate the distribution of the abundance of immunoprecipitated clones, as recently demonstrated for RNA-Seq data 12 . Because the sample preparation and sequencing steps introduce similar biases, this distribution family fits the data quite well (Fig. 2b) . We calculated the generalized Poisson parameter values for each input abundance level 13 and regressed these parameters to form our null model for the calculation of enrichment significance (P-values) of each clone (Fig. 2c) . Comparing the two PhIP-Seq replicates for patient A revealed that the most significantly enriched clones were the same in both replicas (Fig. 2d) , highlighting the reproducibility of the assay. This contrasts dramatically with a comparison of two different patients, as the enrichment of peptides is highly patientspecific ( Supplementary Fig. 3 ). Performing a negative-control PhIP-Seq experiment identified phage capable of binding to the slurry of Protein A and Protein G magnetic beads in the absence of patient antibodies. We thus defined patient A-positive clones as those clones with a reproducible -log 10 P-value greater than a cutoff (Fig. 2d , dashed red line) but not significantly enriched on beads alone (P < 10 −3 ). Patient A-positive clones included the expected SAPK4-targeted, positive-control peptide (P < 10 −15 ), the expected NOVA1 autoantigen (P < 10 −15 ) and six additional candidate autoantigens ( Table 2) .
We tested three of these predicted autoantigens (TGIF2LX, DBR1 and PCDH1) by expressing full-length protein in 293T cells and immunoblotting with patient cerebrospinal fluid. TGIF2LX (TGFBinduced factor homeobox 2-like, X-linked) was confirmed as a novel autoantigen, as we detected strong immunoreactivity at the expected molecular weight (Fig. 3a) . Although full-length DBR1 and PCDH1 were expressed well in 293T cells (data not shown), they were not detected by cerebrospinal fluid antibodies. We observed two bands in the untransfected lysate migrating at ~50 and 62 kDa, representing endogenously expressed proteins that correspond either to untested candidates or to false negatives of the PhIP-Seq assay. Strikingly, the hypothetical protein LOC26080 had seven distinct peptides that were significantly enriched, and they all appeared to share a nine-residue repetitive motif. We used MEME software 14 to characterize this motif, which represents the likely epitope recognized by patient A's autoantibodies (Fig. 3b) .
Analysis of two PND patients with uncharacterized autoantibodies
Having established that PhIP-Seq could reliably identify known and previously unreported autoantigens, we examined cerebrospinal fluid from two additional patients who had suggestive PND symptoms but tested negative for a panel of commercially available PND autoantigens. Patient B was a 59-year-old female with NSCLC, who had dysarthria, ataxia, head titubation and muscular rigidity. PhIP-Seq analysis yielded three particularly interesting candidate autoantigens: TGIF2LX, CTAG2 (cancer/testis antigen 2) and GAD65 (glutamate decarboxylase 2) ( Table 2) . Both TGIF2LX and CTAG2 were confirmed by immunoblotting (Fig. 3c) . We were surprised to find that patient B, like patient A, was also strongly autoreactive against TGIF2LX. The enriched peptide was distinct from but its sequence overlapped that of the TGIF2LX peptide enriched in patient A's cerebrospinal fluid (Fig. 3d) .
CTAG2 is a member of a family of cancer/testis antigen (CTAG) proteins that are normally restricted to germ cells of the developing gonads and/or the adult testis but are frequently expressed in cancers and often elicit antitumor immune responses [15] [16] [17] . TGIF2LX, like CTAG2, is normally restricted to testis 18, 19 but can also be expressed in cancer cells in either sex, suggesting that it may be a new CTAG family member. As a negative control, we found TGIF2LX reactivity to be absent in the cerebrospinal fluid of three patients with non-PND CNS autoimmunity and oligoclonal immunoglobulin bands (Supplementary Fig. 4) . Having confirmed TGIF2LX autoreactivity in two individuals with NSCLC, we wondered whether it could be a biomarker for this disease. However, the serum of 15 other NSCLC patients without PND did not contain TGIF2LX antibodies detectable by immunoblotting (Supplementary Fig. 5 ).
Neither CTAG2 nor TGIF2LX is expressed in the brain, and thus neither is likely to explain the neurological syndrome experienced by patient B. GAD65, however, is the rate-limiting enzyme in the synthesis of the inhibitory neurotransmitter GABA and is also a well-characterized autoantigen targeted in the autoimmune disorder stiff person syndrome. Two nonoverlapping GAD65 peptides derived from the domain known to be targeted by pathogenic autoantibodies in individuals with this syndrome 20, 21 were enriched in patient B's cerebrospinal fluid. A commercial radioimmunoassay confirmed the presence of high-titer GAD65 autoantibodies (5.12 nmol/L; >250-fold above the reference range). Surprisingly, however, direct immunoblotting with cerebrospinal fluid from patient B did not show reactivity (Fig. 3c) , suggesting that denatured GAD65 epitopes are not recognized by patient B's antibodies. Successful immunoprecipitation of GAD65 from the same cell lysate with patient B's cerebrospinal fluid confirmed this hypothesis (Fig. 3e) . Patient C, a 59-year-old female with PND that arose after she developed melanoma, had unusual symptoms that included horizontal gaze palsy. PhIP-Seq analysis of patient C's cerebrospinal fluid yielded five significantly (P < 10 −4 to 10 −15 ) enriched peptides from two homologous members of the tripartite motif (TRIM) family, TRIM9 and TRIM67 ( Table 2) . Both candidate autoantigens were confirmed by immunoblotting lysates from TRIM9-or TRIM67-overexpressing cells (Fig. 3f) . TRIM67 is expressed in some normal tissues (including skin) and is often highly expressed in melanoma 19 . TRIM9 has recently emerged as a brain-specific E3 ubiquitin ligase and has been implicated in neurodegenerative disease processes 22 . Based on their high degree of homology, our data suggest the possibility that immune responses to the cancer, targeting TRIM67, might have spread to or cross-reacted with TRIM9 in the CNS (Supplementary Fig. 6 ). Neither TRIM9 nor TRIM67 autoreactivity was detected in the cerebrospinal fluid of three patients with non-PND CNS autoimmunity (Supplementary Fig. 4) .
In total, 16 of the candidate autoantigens in Table 2 were available to us as full-length Gateway Entry clones from the ORFeome collection 23 . Of these, ten were not confirmed by immunoblotting or immunoprecipitation of the full-length protein. We wondered whether this indicated a high rate of false-positive discovery inherent to PhIP-Seq, or rather a requirement that the peptides be presented with intact conformation, as was the case for GAD65. We made nine of these ten candidate T7 clones, plus two additional highconfidence T7 clones for which no full-length ORF was available. In a dot blot assay, each of these clones exhibited immunoreactivity above background with the appropriate patients' spinal fluid as predicted by the PhIP-Seq data set ( Fig. 3g and Supplementary Fig. 7 ). This finding indicates that PhIP-Seq analysis can have a low rate of false-positive discovery, and supports the hypothesis that the 36-amino acid peptides retain a significant amount of secondary structure when displayed on the T7 coat.
PhIP-Seq can identify peptide-protein interactions
The utility of the T7-Pep library is not limited to autoantigen identification. To explore a more general application, we have used the library in an in vitro, peptide-protein, 'two-hybrid' interaction experiment with GST-RPA2 (replication protein A2) as bait for the T7-Pep library. We again used the generalized Poisson method for determining the significance of phage clones' enrichment. Whereas GST alone did not significantly enrich any library clones (P < 10 −4 ; Supplementary Fig. 8 peptide from the known interactor SMARCAL1 (P < 10 −14 ; Fig. 4) , among others (Supplementary Table 3 ). The enriched SMARCAL1 peptide contains a previously identified motif that binds RPA2 (refs. 24,25) . Four other proteins are known to contain this motif (UNG2, TIPIN, XPA and RAD52), but most motifs were significantly disrupted by the positions of the breaks between peptides ( Table 3) .
One peptide from UNG2 retained most of the motif and that peptide was correspondingly enriched (P < 10 −5 ), demonstrating the power of this approach to identify interaction motifs.
DISCUSSION
We have developed a proteomic technology based on a phage library that uniformly expresses the complete human peptidome. Combining the T7-Pep phage library with high-throughput DNA sequencing enables a variety of proteomic investigations. In addition to applications in autoimmune disease, our approach can be used to identify peptideprotein interactions and can be a viable alternative to two-hybrid analyses. From a methodological perspective, the robust single-round enrichment signals and the ability to adapt the assay to a 96-well format suggests the feasibility of performing automated PhIP-Seq screens on large sets of samples. Antibodies bind protein antigens by a variety of mechanisms and several studies have uncovered some general themes underlying these interactions. For instance, antibody binding surfaces on natively folded proteins tend to be dominated by 'discontinuous' epitopes, which are patches of ~4 to 14 amino acid side chains formed by two or more noncontiguous peptides brought into proximity during protein folding 26, 27 . If the protein is divided into its constituent peptides, antibody affinity is expected to decrease owing to (i) the loss of contacts contributed by noncontiguous residues, and (ii) the increased entropic costs of binding a free peptide as opposed to the natively constrained peptide. The degree to which individual peptides interact with a given antibody is difficult to predict, and is expected to vary widely. Although our study demonstrates the utility of 36-amino acid peptides, further work will be required to define the precise false-negative discovery rate inherent in the use of the T7-Pep library. Autoantibodies that target normally inaccessible epitopes have also been reported, such as those that recognize proteolytic cleavage products 28, 29 , misfolded proteins or protein aggregates 30, 31 . In circumstances such as these, antigen discovery with full-length, folded proteins may be less sensitive than with shorter peptides.
By performing PhIP-Seq with cerebrospinal fluid from a PND patient (patient A) with a known NOVA autoantibody, we identified this protein as well as a previously unreported, testis-restricted 19 autoantigen (TGIF2LX). As we also found TGIF2LX antibodies in the spinal fluid of a second PND patient with NSCLC, this protein may represent a new cancer/testis antigen family member, and may warrant further investigation as a biomarker for PND. PhIPSeq analysis of cerebrospinal fluid from two PND patients with uncharacterized antibodies (patients B and C) uncovered likely neuronal targets of their autoimmune syndromes. In patient B, high-titer GAD65 antibodies bound two distinct peptides from the region of the protein associated with stiff person syndrome. Notably, GAD65 targeting in stiff person syndrome occurs more often in people without cancer, raising the possibility that at least part of this neurological syndrome may have been unrelated to the patient's cancer. Because management of stiff person syndrome differs from that of PND, this finding underscores the utility of unbiased antibody profiling to distinguish between deceptively similar disease states 32 . In patient C, we identified TRIM9 as a likely neuronal autoantigen and suggest the possibility of epitope spreading from tumor-derived TRIM67 as a potential mechanism. It should be noted that demonstration of a protein's autoreactivity is not evidence for its role in disease pathogenesis, as the autoantibodies might be incidental in nature, arise because of epitope spreading or might simply exhibit noncognate cross-reactivity.
Several notable features of our approach emerged during this proofof-concept study. We found that patient antibodies targeting GAD65 robustly recognized two 36-amino acid peptides but not the corresponding denatured full-length protein, indicating that an important degree of conformational information is retained in the peptide library. Second, for proteins with known crystal structures, using short peptides can facilitate determination of the antibody clonality, as well as the location of the targeted epitope. Finally, the simultaneous quantification of a large number of peptide enrichments permits the discovery of epitope motifs. Autoantibodies from patient A targeted seven peptides from a repetitive hypothetical protein, and we were thus able to calculate a motif that most likely represents the antigenic epitope.
The T7-Pep library could be improved in several ways. The generation of longer oligos will decrease the complexity of the library, thereby increasing the sampling depth and making it possible to generate domain libraries that capture more protein-folding units. In addition, PhIP-Seq with libraries of peptides from human pathogens could permit rapid analysis of antibodies to infectious agents, thus aiding vaccine research and the diagnosis of infectious diseases.
In conclusion, we have taken a synthetic biological approach to develop a proteomic reagent useful in translational medicine. Combining this reagent with high-throughput DNA sequencing permits unbiased and quantitative analysis of autoantibody repertoires in humans. PhIP-Seq thus complements existing proteomic technologies in the study of autoimmune diseases for which the relevant autoantigens remain unknown.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nbt/index.html.
Note: Supplementary information is available on the Nature Biotechnology website.
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Estimation of general Poisson model parameters and regressions.
We assessed several distribution families for their ability to appropriately model the PhIP-Seq null distribution, and found the two-parameter generalized Poisson distribution to be the best
For each value of input read number that had at least 50 corresponding clones, we used the following maximum likelihood estimators to calculate the values of lambda (λ) and theta (θ) for the corresponding distribution of n immunoprecipitation reads (x i ) 13 .
Upon calculation of λ across all the input read numbers, we found it to be approximately constant. For each experiment, we thus regressed this parameter to be equal to the mean of all calculated λs (Fig. 2c) . Calculation of θs for all input values revealed the near linearity of this parameter, and so we linearly regressed this parameter before calculating the P-values.
Validation of full-length candidate autoantigens. We used the ORFeome collection of full-length proteins, which was generated by PCR and Gateway recombinational cloning 34 , as a source for testing autoantigen candidates by immunoblot. Entry vectors were recombined into the appropriate mammalian expression vector (cytomegalovirus promoter driving ORF expression with either C-terminal GFP fusion or N-terminal FLAG epitope tag) and miniprepped for transient transfection.
293T cells were plated 24 h before transfection at a density of 0.8 million cells per well of a 6-well plate and grown in DMEM containing 10% FBS. TransIT-293T transfection reagent (Mirus, MIR 2700) was mixed with 2 µg expression plasmid per well, and added to the cells. After 24 h, cells were harvested in 200 µl standard 1× RIPA-based laemmli/DTT sample buffer with complete protease inhibitor cocktail (Roche) and sonicated for 30 s. Insoluble material was removed by centrifugation. Lysate (2-20 µl) was run out on 4-20% Bis-Tris polyacrylamide gels and transferred onto nitrocellulose using the iBlot system (Invitrogen). Membranes were blocked 1 h in 5% milk and then stained with either patient cerebrospinal fluid (1:250 to 1:1,000) or the appropriate primary anti-GFP (JL-8 monoclonal antibody; Clontech, 632381) or anti-FLAG (M2 monoclonal antibody; Sigma-Aldrich, F9291) antibody in 2.5% milk, TBST. Human antibody from cerebrospinal fluid was detected with 1:3,000 peroxidase-conjugated goat affinity purified anti-Human IGG (whole molecule) secondary antibody (MP Biomedicals, 55252) in 2.5% milk, TBST.
For the commercial GAD65 radioimmunoassay (RIA 81596; Mayo Medical Laboratories), spinal fluid was diluted eightfold in PBS and shipped on dry ice to the Mayo Clinic Medical Laboratories.
For immunoprecipitation-western blotting, cell lysate was harvested in standard RIPA buffer with complete protease inhibitor cocktail and sonicated for 30 s. Insoluble material was removed by centrifugation. Lysate (150 µl) was mixed with 1 µg of patient antibodies and rotated overnight at 4 °C. A 40 µl slurry of 1:1 mix of Protein A-coated magnetic Dynabeads and Protein Gcoated magnetic Dynabeads was added to each tube. Tubes were rotated 4 h at 4 °C. Beads were washed 3 times in 500 µl RIPA buffer, and then harvested in 25 µl of laemmli/DTT sample buffer. The immunoprecipitated protein and 10% of the input lysate were subjected to SDS-PAGE analysis as above, and protein was detected by staining for the protein tag (e.g., GFP). Dot blot validation of candidate autoantigens. Individual clones were made by synthesizing the peptide-encoding insert as a single, long DNA oligo (IDT, Ultramer) that was PCR amplified and then cloned into T7FNS2 in the same way as described for the library. Clones were sequence verified and titered. Two microliters of each clone, after normalizing for titer, were spotted directly onto a nitrocellulose membrane and allowed to dry for 30 min. Membranes were blocked with 5% milk, TBST for 1 h at 25 °C, and then stained overnight at 4 °C with 1 µg/ml of cerebrospinal fluid antibody diluted in a solution containing a 1:1 mix of 5% milk, TBST and T7 10-3b-FLAG phage lysate. Human antibody from cerebrospinal fluid was then detected with 1:3,000 peroxidaseconjugated goat affinity-purified secondary anti-Human IGG (whole molecule; MP Biomedicals, 55252) in 2.5% milk, TBST. Quantification was performed by scanning developed films and analyzing the .tiff file with ImageJ software.
